PureTech Health (NASDAQ:PRTC) Shares Gap Down – Here’s What Happened

PureTech Health plc (NASDAQ:PRTC)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $22.56, but opened at $22.05. PureTech Health shares last traded at $22.05, with a volume of 361 shares.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PRTC. Leerink Partnrs upgraded PureTech Health to a “strong-buy” rating in a report on Monday, September 9th. Leerink Partners started coverage on PureTech Health in a research note on Monday, September 9th. They issued an “outperform” rating and a $45.00 price target for the company.

PureTech Health Price Performance

The stock’s 50-day moving average price is $21.18 and its 200-day moving average price is $22.71.

Hedge Funds Weigh In On PureTech Health

A hedge fund recently bought a new stake in PureTech Health stock. Birch Hill Investment Advisors LLC acquired a new position in PureTech Health plc (NASDAQ:PRTC) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 302,000 shares of the company’s stock, valued at approximately $7,550,000. Birch Hill Investment Advisors LLC owned approximately 1.26% of PureTech Health at the end of the most recent quarter. 0.04% of the stock is owned by institutional investors.

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.